Open access
Sep 2026
Actionable genetic landscape and dynamics in circulating DNA from 12,827 patients with metastatic breast cancer
This large collection of MBC cfDNA data is envisioned as an invaluable resource for the design and planning of future clinical trials, and cfDNA testing is now recommended in multiple advanced malignancies, including eligibility assessment for clinical trials.
I. Leshchiner, A. Medford, J. Cha et al.
· Nature Communications · 0 citations